Clovis Oncology (NASDAQ:CLVS) shares are surging in today’s pre-market trade after its Rubraca demonstrated progression-free survival versus placebo for ovarian cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company presented the data from the supporting ATHENA trial at the European Society of Medical Oncology (ESMO) Congress in Paris.
More details to follow…
Read full Disclosure